Next 10 |
home / stock / rhhbf / rhhbf articles
Novartis AG (NYSE:NVS) reportedly plans to slash up to 680 positions in its development organization, aiding in drug market launches. The...
Friday, LumiraDx Limited (NASDAQ: LMDX) appointed joint administrators for two subsidiaries. The administrators signed a definitive ...
Poseida Therapeutics Inc (NASDAQ: PSTX) released early efficacy and safety results from its Phase 1 study of P-BCMA-ALLO1, its BCMA-targeted a...
Roche Holdings AG (OTC: RHHBY) announced results from the Phase 3 INAVO120 study of the investigational therapy, inavolisib, in combinati...
Roche Holding AG (OTC: RHHBY) has agreed to acquire a privately held obesity company Carmot Therapeutics, seeking to challenge ...
Sarepta Therapeutics Inc (NASDAQ: SRPT) released topline results from EMBARK (Study SRP-9001-301) Phase 3 study of Elevidys (delandistrogene m...
Roche Holding AG (OTC: RHHBY) inked a deal to acquire Telavant Holdings, Inc. for $7.1 billion. As per the terms, Roche will pa...
Roche Holdings AG's (OTC: RHHBY) nine months sales increased by 1% (down 6% in CHF) to CHF 44.1 billion, even though the co...
Monte Rosa Therapeutics Inc (NASDAQ: GLUE) entered into a strategic collaboration and licensing agreement with Roche Holdings AG (OT...
News, Short Squeeze, Breakout and More Instantly...
Economist Impact report, Advancing the frontier of health and technology integration: The 2023 Digital Health Barometer highlights opportunities in digitalisation of healthcare Canada NewsWire The report shows digital health technologies demonstrate value, yet integrating th...
Development in Alzheimer's disease diagnosis in Canada: New tests help patients and caregivers make timely decisions Canada NewsWire Roche's Cerebrospinal Fluid (CSF) assays address unmet needs in the detection of amyloid pathology by offering greater accessibility and support...